NASDAQ:VTRS
Viatris (VTRS)
16.28
-0.00 (0.00%)
as of Aug 11, 2026, 8:00:00 pm Market Open.
78 watching
Financials 
Technical Analysis 0
Investor Insights
Aug 12, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Viatris (VTRS-Q) presents a mixed outlook according to recent expert reviews. One expert appreciates its current valuation, stating it trades at a low PE ratio of 7-8x, indicating potential for growth if the company focuses more on enhancing shareholder value. While the sentiment is positive overall, it is noted that the company has low growth prospects and that it was spun out of Pfizer, which may contribute to its smaller market footprint. Another expert emphasizes caution, suggesting that investors should prioritize companies that are 'on sale' within the healthcare sector. Overall, Viatris seems to be a company with potential benefits, but also significant caveats regarding growth and market presence.
Consensus
Cautious
Valuation
Undervalued
Similar
Teva,TEVA
PAST TOP PICK
(A Top Pick Jan 27/22, Down 17%) It sold a division for $2 billion with a chunk of that money going to the purchase of a couple of eye-care companies. It is trading at 4X earnings and buying back lots of stock. It covers a number of areas including oncology, the central nervous system, anesthetics and will narrow this down to areas such as diabetes and cardio vascular which have good growth ahead of them.
Lorne SteinbergOwned
Pharma & Healthcare
BUY
Pharmaceutical company that sells generic drugs.
Healthy dividend yield and cash flow.
About to close on M&A deal.
Big question is whether company will return capital to shareholders (share buybacks).
Shares very cheap at current price.
Lorne SteinbergOwned
Pharma & Healthcare
HOLD
Trading at 4x earnings. Disappointed Wall Street. Finally stabilized earnings. Asset sale later this year will bring in a fair bit of money. He anticipates a share buyback, decent cashflow, decent dividend to continue. Strategy becoming more apparent.
Lorne SteinbergOwned
Pharma & Healthcare
BUY
Later this year they will complete the sale of a business and the company could (probably) buy back 10% of shares with that cash. Be patient. Trades at only 3-4x earnings. So a buyback will be a big boost to shares. Early on their reports disappointed but lately has been alright. This flies under the radar.
Pharma & Healthcare
BUY
It's the cheapest stock he owns, trading at 3x earnings. They generate fresh cash flow. They close the sale in late 2022 of one of their divisions. He expects them to use a major share buyback with those proceeds, and a bump in the share price finally. This is an incredible value stock or everybody is missing something. We'll see.
Lorne SteinbergOwned
Pharma & Healthcare
HOLD
Underperformer. Profitable, free cashflow positive. Out of favour. Profits from sale of biosimilar business will be used to buy back shares, which he approves of. Compellingly cheap at 3x earnings. Paying down debt.
Lorne SteinbergOwned
Pharma & Healthcare
HOLD
Cheapest stock in his portfolio, at a PE of 4. Free cashflow and dividend payer. Market didn't like lukewarm guidance. Either he's missing something, or it won't take much for the stock to outperform.
Lorne SteinbergOwned
Pharma & Healthcare
DON'T BUY
Includes boring drugs, which provide consistent cashflows. Bit of growth in its biosimilar business, but talk of selling that. Range bound, limited growth, fair amount of debt, but tolerable for the type of assets. Low margin generics are more sensitive to inflationary risks. Dividend is probably safe.
Pharma & Healthcare
TOP PICK
Huge free cashflow. PE ratio is 4, not 14, but 4. Stock disappointed investors last year, Q3 was above expectations, expects Q4 to be strong. Needs very little to go right for them to do well. Went up in the recent down market. How can you not buy it? Yield is 3.25%. (Analysts’ price target is $18.62)
Lorne SteinbergOwned
Pharma & Healthcare
DON'T BUY
Among the biggest losers on the S&P in 2021
#6, down 28%. It's a Pfizer generic drug spin-off. Bad timing--Biden wants to reign in generic drug pricing. VTRS expects no earnings growth this year or next. They hold patent drugs under pressure as more knock-offs hit the market. It's the ultimate value trap. It sells for less than 4x earnings, but this is usually a red flag. Better to buy big pharmas.
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Dec 22/20, Down 24%) By far the cheapest cost (and highest value) stock in their portfolio. A fist banging buy. They have drugs like the EpiPen and others for asthma. They pay a reasonable dividend and it trades at 4x earnings. Even at 8x, it would be very cheap. He is not concerned about legal issues surrounding the EpiPen - you simply need their product.
Lorne SteinbergOwned
Pharma & Healthcare
STRONG BUY
PE is around 5. Cheapest stock in his portfolio. First quarter, they underdelivered and the stock was punished. Last quarter, management delivered. He owns it for capital appreciation. Risk/reward is highly stacked in favour of the reward side. A bargain.
Lorne SteinbergOwned
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Dec 22/20, Down 17%) Incredibly cheap, core holding for him. In generics, with some coming off patent. Very solid pipeline. Last quarter was surprisingly strong. Solid dividend.
Lorne SteinbergOwned
Pharma & Healthcare
BUY
It is the cheapest stock he owns. They came to market and disappointed with their first quarter. The are being punished by the street. They are now a show-me stock. Little needs to go right for this company.
Lorne SteinbergOwned
Pharma & Healthcare
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
